secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001567892-24-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt FY2023 net sales $1.87B, EBITDA $572M; guides FY2024 EBITDA $520-560M
--------------------------------------------------------------------------------

- FY2023 net sales $1.866B, down 2.5% YoY; Q4 net sales $469.3M (-4.1%).
- FY2023 Adjusted EBITDA $571.9M, above guidance range; Q4 EBITDA $123.8M vs $175.5M.
- Specialty Brands Q4 net sales $270.7M (-15.6%); impacted by Amitiza generic competition.
- Specialty Generics Q4 net sales $198.6M (+17.8%); strong finished-dosage demand.
- 2024 guidance: net sales $1.80-1.90B, Adj. EBITDA $520-560M; FDA approved SelfJect injector.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/0001567892-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/mnk-20240326.htm
  HTML page:      https://secwatch.observer/filing/0001567892-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer